Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$47.60 USD
+0.34 (0.72%)
Updated May 29, 2024 04:00 PM ET
After-Market: $47.67 +0.07 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JANX 47.60 +0.34(0.72%)
Will JANX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
Other News for JANX
Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Analyst Ratings For Janux Therapeutics
Buy Rating Affirmed for Janux Therapeutics with Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials
Janux Therapeutics price target raised by $13 at H.C. Wainwright, here's why